Review: taking Phenergan and Requip together


Summary

Drug interactions are reported among people who take Phenergan and Requip together. This review analyzes the effectiveness and drug interactions between Phenergan and Requip. It is created by eHealthMe based on reports of 228 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Phenergan and Requip >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Phenergan

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. (latest outcomes from Phenergan 14,168 users)

Requip

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. (latest outcomes from Requip 12,791 users)

On Aug, 23, 2016

228 people who take Phenergan, Requip are studied.


Number of reports submitted per year:

Phenergan and Requip drug interactions.

Drug effectiveness over time:

Phenergan:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Requip:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 100.0% - (2 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Phenergan:
  • female: 66.0% - (2 of 3 people)
  • male: 0.0% - (0 of 0 people)
Requip:
  • female: 66.0% - (2 of 3 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Phenergan:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 50.0% - (1 of 2 people)
  • 40-49: 100.0% - (1 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Requip:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 50.0% - (1 of 2 people)
  • 40-49: 100.0% - (1 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • ammonia decreased
  • amnesia
  • aphasia
  • asthenia
  • azotaemia
  • vomiting
  • acute respiratory distress syndrome
  • hyperglycaemia
  • pulmonary embolism
  • activities of daily living impaired
1 - 6 months:
  • sleepy
6 - 12 months:
  • obsessive rumination
1 - 2 years:
  • sleepy
  • sleep disorder
10+ years:
  • sleep disorder
not specified:
  • nausea
  • pain
  • anxiety
  • vomiting
  • fatigue
  • chest pain
  • dyspnoea
  • headache
  • dizziness
  • depression

Most common drug interactions by gender *:

female:
  • nausea
  • pain
  • vomiting
  • anxiety
  • fatigue
  • headache
  • chest pain
  • diarrhoea
  • dizziness
  • fall
male:
  • depression
  • dyspnoea
  • fatigue
  • nausea
  • pain
  • anxiety
  • chest pain
  • cough
  • dizziness
  • injury

Most common drug interactions by age *:

20-29:
  • nausea
  • pulmonary embolism
  • anxiety
  • cholecystitis acute
  • depression
  • emotional disorder
  • gastrooesophageal reflux disease
  • headache
  • hypertension
  • hypoglycaemia
30-39:
  • sleepy
  • abdominal pain upper
  • anxiety
  • nausea
  • pulmonary embolism
  • fall
  • pain
  • thyroid neoplasm
  • vomiting
  • dyspnoea
40-49:
  • drug ineffective
  • fatigue
  • insomnia
  • nausea
  • pain
  • fall
  • vomiting
  • drug withdrawal syndrome
  • dyspnoea
  • muscle spasms
50-59:
  • gastrooesophageal reflux disease
  • chest pain
  • pain
  • dizziness
  • headache
  • asthma
  • dyspnoea
  • neuropathy peripheral
  • restless legs syndrome
  • depression
60+:
  • diarrhoea
  • nausea
  • hypotension
  • fatigue
  • cardiac failure congestive
  • dehydration
  • vomiting
  • abdominal pain
  • aggression
  • pain

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Phenergan and Requip?

Can you answer these questions?

More questions for: Phenergan, Requip

You may be interested in these reviews

More reviews for: Phenergan, Requip

On eHealthMe, Phenergan (promethazine hydrochloride) is often used to treat nausea. Requip (ropinirole hydrochloride) is often used to treat restless leg syndrome. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.